Bionomics Provides a Review of 2023 and of 2024 Plans

January 22, 2024

https://www.globenewswire.com/news-release/2024/01/22/2812832/0/en/Bionomics-Provides-a-Review-of-2023-and-of-2024-Plans.html

Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food & Drug Administration (FDA) anticipated in Q2’24.

Read more at globenewswire.com

Related news for (BNOX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.